Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,34
KB0,72
PKN42,5242,55-0,28
Msft214,22214,24-0,01
Nokia3,56953,5710,00
IBM117,5117,52-6,37
Daimler AG48,6248,625-0,37
PFE37,4237,43-0,98
20.10.2020 17:15:01
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2020 17:13:30
Bioinvent (Stockholm)
Poslední obchod Změna (%) Změna (SEK) Objem obchodů (SEK)
1,59 -2,21 -0,04 4 133 299
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.10.2020
Popis společnosti
Obecné informace
Název společnostiBioInvent International AB
TickerBINV
Kmenové akcie:Ordinary Shares
RICBINV.ST
ISINSE0000789711
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 30.06.2020 72
Akcie v oběhu k 30.06.2020 594 118 262,32
Počet akcionářů k 31.12.2019 10 109
MěnaSEK
Kontaktní informace
UliceIdeon Science Park
MěstoLUND
PSČ223 70
ZeměSweden
Kontatní osobaMartin Welschof
Funkce kontaktní osobyPresident, Chief Executive Officer
Telefon46 462 868 550
Fax46462110806
Kontatní telefon46 462 868 550

Business Summary: BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403, BI-204 and BI-505, as well as licenses. BioInvent is active in the co-development of intellectual property through strategic product alliances with ThromboGenics Ltd and Roche Group. It has has entered into several product partnerships with Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. As of December 31, 2011, the Company had one wholly owned subsidiary BioInvent Finans AB, engaged in the administration of warrants issued by the Company. As of December 31, 2011, the Company’s largest shareholder was JP Morgan Bank. In May 2014, the Company sold back all its rights to product candidate ADC-1013 to its former partner Alligator Bioscience AB.
Financial Summary: BRIEF: For the six months ended 30 June 2020, BioInvent International AB revenues decreased 36% to SEK32.4M. Net loss increased 19% to SEK72M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other operating income and costs decrease of 78% to SEK849K (income), Sales and administrative costs increase of 4% to SEK15.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSBiological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 20.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardLeonard Kruimer6224.04.201824.04.2018
President, Chief Executive OfficerMartin Welschof5801.09.201801.09.2018
Chief Financial OfficerStefan Ericsson56
Senior Vice President, Technical OperationsKristoffer Rudenholm Hansson4501.01.2016
Chief Scientific OfficerBjorn Frendeus4631.08.2018
Chief Medical OfficerAndres McAllister6301.01.2017